We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.
If you are interested in this treatment, please visit the program details at Clinical Trials to find out how you may be able to be treated before FDA approval, and health insurance providers acknowledgement of this new treatment for US patients.
You must be logged in to post a comment.